The WNT974-artesunate combination efficiently targeted the PI3K/Akt/mTOR axis and promoted KRAS degradation, which is desirable in resistant CRC cases, albeit data on long-term tumor suppression and survival are limited. Here, AKT1 is linked to neoplasm.